ERBB2 and gastric cancer: It has now been tried in the treatment of gastric carcinoma and has been shown to increase survival in gastric cancers when HER-2 is overexpressed. More than 20% of gastric cancers now are found to show overexpression of HER-2 and this percentage increases to 33% in gastroesophageal junction tumors [7].